Skip to main content

Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication

By June 15, 2022July 15th, 2022Ankylosing Spondylitis

There is limited information regarding treatment experience of patients with axial spondyloarthritis/ ankylosing spondylitis (axSpA/AS) receiving biological disease-modifying antirheumatic drugs (bDMARDs). This study shares the experience of 128 patients currently taking a bDMARD therapy for axSpA or AS. In this predominantly female sample of bDMARD-treated patients with axSpA/AS and high disease activity, the majority expressed treatment satisfaction. However, most experienced wear-off between doses and relied on supplemental medications, including opioids, to manage symptoms.


Click here to read more

Click to read more